BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 15871635)

  • 1. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
    Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
    Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
    Brown F; Banken L; Saywell K; Arum I
    Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
    Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
    Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
    Yu MA; Park JM
    Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
    Paya C; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Pescovitz MD;
    Am J Transplant; 2004 Apr; 4(4):611-20. PubMed ID: 15023154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients.
    Pescovitz MD
    Transpl Infect Dis; 1999; 1 Suppl 1():31-4. PubMed ID: 11565585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
    Asberg A; Rollag H; Hartmann A
    Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New prophylactic treatment strategy for cytomegalovirus disease.
    Lake KD
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S13-6. PubMed ID: 14686230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
    Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
    Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
    Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
    Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
    Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
    Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.
    Cochrane AB
    Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S17-21. PubMed ID: 16990640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
    Oppenheimer F; Gonzalez-Molina M; Rubio M
    Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
    Perrottet N; Decosterd LA; Meylan P; Pascual M; Biollaz J; Buclin T
    Clin Pharmacokinet; 2009; 48(6):399-418. PubMed ID: 19650679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days.
    Welker H; Farhan M; Humar A; Washington C
    Transplantation; 2010 Dec; 90(12):1414-9. PubMed ID: 21076372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
    Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
    Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.